NFKB1 and Miyoshi myopathy: Nuclear factor-kappa B (NF-κB) is a major growth and survival signalling pathway in MM; indeed, the initial rationale for therapeutic use of Bortezomib was, in part, based on its ability to inhibit NF-κB activation (Russo et al, 2001; Adams, 2002; Hideshima et al, 2002).